Roche Holding (SWX:ROG) - Stock Price, News & Analysis

ROG Stock Overview

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

About the company

ROG fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	5/6

Rewards

Trading at 65.5% below our estimate of its fair value

Earnings are forecast to grow 10.95% per year

Pays a reliable dividend of 3.59%

Trading at good value compared to peers and industry

Risk Analysis

Has a high level of debt

Large one-off items impacting financial results

Roche Holding AG Competitors

Novartis

SWX:NOVN

CHF 201.6b

Dottikon ES Holding

SWX:DESN

CHF 3.4b

Cosmo Pharmaceuticals

SWX:COPN

CHF 1.3b

AstraZeneca

LSE:AZN

UK£197.1b

Price History & Performance

Summary of all time highs, changes and price drops for Roche Holding
Historical stock prices
Current Share Price	CHF 267.20
52 Week High	CHF 288.20
52 Week Low	CHF 212.90
Beta	0.15
11 Month Change	-3.57%
3 Month Change	9.73%
1 Year Change	4.93%
33 Year Change	-22.82%
5 Year Change	-4.25%
Change since IPO	923.76%

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Sep 10

Recent updates

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Sep 10

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

Shareholder Returns

	ROG	CH Pharmaceuticals	CH Market
7D	-5.1%	-4.9%	-3.4%
1Y	4.9%	15.6%	5.8%

Return vs Industry: ROG underperformed the Swiss Pharmaceuticals industry which returned 15.6% over the past year.

Return vs Market: ROG matched the Swiss Market which returned 5.8% over the past year.

Price Volatility

Is ROG's price volatile compared to industry and market?
ROG volatility
ROG Average Weekly Movement	3.1%
Pharmaceuticals Industry Average Movement	3.3%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.2%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: ROG has not had significant price volatility in the past 3 months.

Volatility Over Time: ROG's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas.

Roche Holding AG Fundamentals Summary

How do Roche Holding's earnings and revenue compare to its market cap?
ROG fundamental statistics
Market cap	CHF 215.08b
Earnings (TTM)	CHF 10.62b
Revenue (TTM)	CHF 60.58b

20.0x

P/E Ratio

3.5x

P/S Ratio

Is ROG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ROG income statement (TTM)
Revenue	CHF 60.58b
Cost of Revenue	CHF 15.43b
Gross Profit	CHF 45.16b
Other Expenses	CHF 34.54b
Earnings	CHF 10.62b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	13.33
Gross Margin	74.54%
Net Profit Margin	17.53%
Debt/Equity Ratio	104.8%

How did ROG perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

72%

Payout Ratio

ROG Stock Overview

Rewards

Risk Analysis

Roche Holding AG Competitors

SWX:NOVN

CHF 201.6b

SWX:DESN

CHF 3.4b

SWX:COPN

CHF 1.3b

LSE:AZN

UK£197.1b

Price History & Performance

Recent News & Updates

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

New minor risk - Earnings quality

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

First half 2024 earnings: EPS misses analyst expectations

Recent updates

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

New minor risk - Earnings quality

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

First half 2024 earnings: EPS misses analyst expectations

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)